Skip to main content

A Novel Nomogram for Peritoneal Mesothelioma Predicts Survival



Malignant peritoneal mesothelioma (MPM) is a rare disease treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Estimation of personalized survival times can potentially guide treatment and surveillance.


We analyzed 104 patients who underwent CRS and cisplatin-based HIPEC for MPM. By means of 25 demographic, laboratory, operative, and histopathological variables, we developed a novel nomogram using machine-learned Bayesian belief networks with stepwise training, testing, and cross-validation.


The mean peritoneal carcinomatosis index (PCI) was 15, and 66 % of patients had a completeness of cytoreduction (CC) score of 0 or 1. Eighty-seven percent of patients had epithelioid histology. The median follow-up time was 49 (1–195) months. The 3- and 5-year overall survivals (OS) were 58 and 46 %, respectively. The histological subtype, pre-CRS PCI, and preoperative serum CA-125 had the greatest impact on OS and were included in the nomogram. The mean areas under the receiver operating characteristic curve for the 10-fold cross-validation of the 3- and 5-year models were 0.77 and 0.74, respectively. The graphical calculator or nomogram uses color coding to assist the clinician in quickly estimating individualized patient-specific survival before surgery.


Machine-learned Bayesian belief network analysis generated a novel nomogram predicting 3- and 5-year OS in patients treated with CRS and HIPEC for MPM. Pre-CRS estimation of survival times may potentially individualize patient care by influencing the use of systemic therapy and frequency of diagnostic imaging, and might prevent CRS in patients unlikely to achieve favorable outcomes despite surgical intervention.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3


  1. Yan TD, Brun EA, Cerruto CA, Haveric N, Chang D, Sugarbaker PH. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2007;14:41–9.

    PubMed  Article  Google Scholar 

  2. Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori. 2003;89:269–73.

    PubMed  Google Scholar 

  3. Alexander HR, Hanna N, Pingpank JF. Clinical results of cytoreduction and HIPEC for malignant peritoneal mesothelioma. Cancer Treat Res. 2007;134:343–55.

    PubMed  CAS  Google Scholar 

  4. Antman KH. Current concepts: malignant mesothelioma. N Engl J Med. 1980;303:200–2.

    PubMed  Article  CAS  Google Scholar 

  5. Antman KH, Osteen RT, Klegar KL, et al. Early peritoneal mesothelioma: a treatable malignancy. Lancet. 1985;2(8462):977–81.

    PubMed  Article  CAS  Google Scholar 

  6. Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Intengen ME. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol. 1999;70:6–12.

    PubMed  Article  CAS  Google Scholar 

  7. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon’s role. Langenbecks Arch Surg. 1999;384:576–87.

    PubMed  Article  CAS  Google Scholar 

  8. Katz MH, Barone RM. The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am. 2003;12:673–88.

    PubMed  Article  Google Scholar 

  9. Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003;12:689–701.

    PubMed  Article  Google Scholar 

  10. Feldman AL. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560–7.

    PubMed  Article  CAS  Google Scholar 

  11. Sugarbaker P, Welch L, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12:605–21.

    Article  Google Scholar 

  12. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–42.

    PubMed  Article  Google Scholar 

  13. Deraco M, Nonaka D, Baratti D, et al. prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13:229–37.

    PubMed  Article  Google Scholar 

  14. Sugarbaker PH, Acherman YI, Gonzalez-Moreno S, et al. Diagnosis and treatment of peritoneal mesothelioma: the Washington Cancer Institute experience. Semin Oncol. 2002;29:51–61.

    PubMed  Article  Google Scholar 

  15. Gail MH, Greene MH. Gail model and breast cancer. Lancet. 2000;355(9208):1017.

    PubMed  Article  CAS  Google Scholar 

  16. Dawy Z, Goebel B, Hagenauer J, Andreoli C, Meitinger T, Mueller JC. Gene mapping and marker clustering using Shannon’s mutual information. IEEE/ACM Trans Comput Biol Bioinform. 2006;3:47–56.

    PubMed  Article  CAS  Google Scholar 

  17. Berry DA, Inoue L, Shen Y, et al. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr. 2006:30–6.

  18. Berry SM, Broglio KR, Berry DA. Addressing the incremental benefit of histamine dihydrochloride when added to interleukin-2 in treating acute myeloid leukemia: a Bayesian meta-analysis. Cancer Invest. 2011;29:293–9.

    PubMed  Article  CAS  Google Scholar 

  19. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.

    PubMed  Article  CAS  Google Scholar 

  20. Nash G, Otis CN. Protocol for the examination of specimens from patients with malignant pleural mesothelioma: a basis for checklists. Cancer Committee, College of American Pathologists. Arch Pathol Lab Med. 1999;123:39–44.

    PubMed  CAS  Google Scholar 

  21. Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2009;133:1317–31.

    PubMed  Google Scholar 

  22. Yan TD, Deraco M, Elias D, et al. A novel tumor–node–metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer. 2011;117:1855–63.

    PubMed  Article  Google Scholar 

  23. Theriault C, Pinard M, Comamala M, et al. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol Oncol. 2011;121:434–43.

    PubMed  Article  CAS  Google Scholar 

  24. Baratti D, Kusamura S, Deraco M. Circulating CA125 and diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2009;35:1198–9.

    PubMed  Article  CAS  Google Scholar 

  25. Rump A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279:9190–8.

    PubMed  Article  CAS  Google Scholar 

  26. Kadota K, Suzuki K, Sima CS, Rusch VW, Adusumilli PS, Travis WD. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. J Thorac Oncol. 2011;6:896–904.

    PubMed  Article  Google Scholar 

  27. Yan TD, Haveric N, Carmignani CP, Chang D, Sugarbaker PH. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer. 2005;103:839–49.

    PubMed  Article  Google Scholar 

  28. Laterza B, Kusamura S, Baratti D, Oliva GD, Deraco M. Role of explorative laparoscopy to evaluate optimal candidates for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal mesothelioma. In Vivo. 2009;23:187–90.

    PubMed  Google Scholar 

Download references


Supported by an NIH intramural grant.


The views expressed in this manuscript are those of the authors and do not reflect the official policy of the NIH/NCI or Department of the Army, the Department of Defense or the United States Government.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Udo Rudloff MD, PhD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Schaub, N.P., Alimchandani, M., Quezado, M. et al. A Novel Nomogram for Peritoneal Mesothelioma Predicts Survival. Ann Surg Oncol 20, 555–561 (2013).

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI:


  • Overall Survival
  • Bayesian Belief Network
  • Malignant Peritoneal Mesothelioma
  • Early Postoperative Intraperitoneal Chemotherapy
  • Peritoneal Carcinomatosis Index